|
Dear Colleagues -- We have just received, and now forward, a safety announcement from FDA regarding dietary supplements containing vinpocetine. Specifically, FDA now warns against the use of vinpocetine by women of childbearing age due to risk of adverse reproductive effects, specifically decreased fetal weight and increased chance of a miscarriage. As the FDA's statement notes, this warning is triggered in part by a recent NTP technical report on prenatal development toxicity in rats and rabbits. FDA believes these tox reports in animals have relevance to humans, hence the warning.
We advise all UNPA members who may be selling vinpocetine to consult with counsel or other experts. UNPA will be consulting with external colleagues and other trade associations to determine what, if any, further steps may be appropriate from industry. We will keep you informed of new developments. Cordially, LDI Comments are closed.
|
